Jlang, It appears that they have identified a r

Jlang,

It appears that they have identified a relatively narrow clinical window for which there is some efficacy.

I believe credit is due for identifying the appropriate time and population for whom these effective.

Two recent studies in NEJM with patients on supplemental oxygen had opposing conclusions.

https://www.nejm.org/doi/full/10.1056/NEJMoa2030340

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide.

https://www.nejm.org/doi/full/10.1056/NEJMoa2030340

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival. No new safety signals were identified.

It appears there may be efficacy, if given to right patients at right time, just the same as for steroids.